NewLink nets $20M Ebola milestone from Merck

NewLink's ($NLNK) Ebola vaccine tie-up with Merck ($MRK) continues to pay off. The Iowa-based company has triggered a milestone payment from the pharma giant worth $20 million, it said last week, and it'll put the money back into its vaccine work for infectious diseases. Release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.